Lv1
36 积分 2024-12-03 加入
Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector
3天前
已完结
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
1个月前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2个月前
已完结
Aggregate data modelling: A fast implementation for fitting pharmacometrics models to summary-level data in R
3个月前
已完结
Study of the combined effects of PTH treatment and mechanical loading in postmenopausal osteoporosis using a new mechanistic PK-PD model
3个月前
已关闭
Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data
3个月前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
3个月前
已完结
An Exposure‐Response Model with Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA‐Mutated Advanced Breast Cancer (BROCADE3) Trial
4个月前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
5个月前
已完结
Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals
6个月前
已完结
皖公网安备34019202002308
